Special Issue

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) in Patients with Cancers

Message from the Guest Editors

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a pivotal therapeutic strategy in the management of hematologic malignancies. Its therapeutic efficacy is largely attributed to the graftversus-leukemia (GVL) effect, wherein donor-derived immune cells target residual malignant cells. Advances in donor selection—such as haploidentical transplantation and the use of alternative stem cell sources—alongside innovations in conditioning regimens, post-transplant immunosuppression, and graft-versus-host disease (GVHD) prophylaxis—such as post-transplant cyclophosphamide—have improved outcomes and expanded donor selection and transplant eligibility. Despite its potential, challenges persist, including graft-versus-host disease, infectious complications, transplant-related mortality, and relapse. This issue will cover updates on ongoing research aimed at refining patient selection, optimizing timing, and integrating new immunotherapeutic strategies to improve the balance between disease control and transplant-related toxicity.

Guest Editors

Dr. Caterina Alati

U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio di Calabria, Italy

Dr. Martina Pitea

Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/253139

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

